Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06883162 · ClinicalTrials.gov registry record · Phase 3
Cannabis-Tobacco Co-Use Treatment Study
A Phase 3 study of Tobacco Use Disorder and Cannabis Use, sponsored by Medical University of South Carolina.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT06883162: Recruiting Phase 3 study of Tobacco Use Disorder and Cannabis Use, sponsored by Medical University of South Carolina.
NCT06883162 is a Phase 3 study of Tobacco Use Disorder and Cannabis Use that is actively recruiting participants, run by Medical University of South Carolina. The registered enrollment target is 200 participants, below the 237-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target (16% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06883162, a Phase 3 study of Tobacco Use Disorder and Cannabis Use, is actively recruiting participants, sponsored by Medical University of South Carolina.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the RECLAIM study is to evaluate the effectiveness of varenicline (sometimes known as Chantix) compared to placebo (an inactive substance) for the treatment of cigarettes and cannabis (marijuana). Varenicline is not FDA approved for the combination treatment of cigarette abstinence and cannabis reduction or abstinence. All participants will also receive counseling and access to online treatment modules during a quit attempt for cigarettes and a reduction attempt for cannabis. This study is being conducted by the Medical University of South Carolina. All procedures are conducted remotely and there is no in-person visits are needed. To qualify, participants must be 18 or older, live in South Carolina, use cigarettes and cannabis, and are interested in quitting cigarettes and reducing cannabis.
Primary Outcome
Biochemically-confirmed 7-day point prevalence abstinence from tobacco
Conditions Studied
Interventions
- DRUG Varenicline
- BEHAVIORAL Counseling
- BEHAVIORAL Psychosocial modules
Study Locations (1)
South Carolina
- Medical University of South Carolina - Charleston - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-05-06 |
| Est. Completion | 2029-01-01 |
| Phase | Phase 3 |
What NCT06883162 shows while recruiting
NCT06883162 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 237-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target (16% lower).
The record links to 5 conditions, with Tobacco Use Disorder appearing as the primary indexed condition, and to 3 interventions - of which Varenicline is the first listed.
NCT06883162 reports a single indexed study location in South Carolina.
Frequently Asked Questions
What is clinical trial NCT06883162 about?
NCT06883162 is a clinical study titled "Cannabis-Tobacco Co-Use Treatment Study". The purpose of the RECLAIM study is to evaluate the effectiveness of varenicline (sometimes known as Chantix) compared to placebo (an inactive substance) for the treatment of cigarettes and cannabis (marijuana). Varenicline is not FDA approved for the combination treatment of cigarette abstinence an...
What is the current status of trial NCT06883162?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 200 participants. The study started on 2025-05-06. Estimated completion is 2029-01-01.
What conditions does trial NCT06883162 study?
This clinical trial studies the following conditions: Tobacco Use Disorder, Cannabis Use, Tobacco Use Cessation, Cannabis Use Disorder, Marijuana Use.
What interventions are being tested in trial NCT06883162?
The interventions under investigation include: Varenicline (DRUG), Counseling (BEHAVIORAL), Psychosocial modules (BEHAVIORAL).
Who is sponsoring clinical trial NCT06883162?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06883162 being conducted?
This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tobacco Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06883162's enrollment target sits among peer trials
200 21st of 70 higher than 47 of 70 other Tobacco Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tobacco Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Non-Nicotine Agents for Smoking Cessation
COMPLETED · Phase 3
-
Naltrexone Augmentation of Nicotine Patch Therapy - 1
COMPLETED · Phase 3
-
Nicotine Regulation for Dual Users of E-cigarettes and Cigarettes
RECRUITING · Phase 2
-
Smoking Cessation CM for Veterans With or at Risk for Cancer
RECRUITING · NA
-
Examining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity
RECRUITING · Phase 2
-
Cannabidiol for Reducing Cigarette Use
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI